Abstract:e18121 Background: Brain metastasis (BM) presents 20-25% of patients with non-small cell lung cancer (NSCLC). Whole brain radiation therapy (WBRT) along with stereotactic radiosurgery (SRS), or surgical resection (SR) or chemotherapy (CXT) were usually used alone or in a combination modality for the treatment. In this study, we purposed to determine the outcome of patients with BM from non-small cell lung cancer treated with EGFR-TKI in combination with conventional therapy. Methods: A total of 201 BM patients with NSCLC were treated sequentially using EGFR-TKI combined with WBRT, or SRS, or SR, or CXT between Jan, 1999 and Nov, 2011 according to our institutional protocol. The median age was 56 yrs (range: 25-80). The histopathological type was predominantly adenocarcinoma (88%) and squamouscell carcinoma (9%), adenosquamous carcinoma (3%). Median follow-up was 28 months (range: 5-80). In addition to the treatment regimen, twelve potential prognostic factors were evaluated including age, gender, smoking status, primary tumor type, tumor size, expression of carcinoembryonic antigen (CEA), intracranial symptoms, lymph nodes metastasis (LNM), number of intracranial metastases, extracerebral metastases, time of taking EGFR-TKI, and TKI-related rash. Results: Median overall survival (OS) for the entire cohort was 29 months (95% CI: 25-34). The OS rate at 1, 2, 3 year were 61%, 38%, and 29%, respectively. On univariate analyses, improved OS was found to be significantly associated with age < 56 yrs (P=0.027), non-expression of CEA (P=0.016), absence of intracranial symptoms (P=0.018), no lymph nodes metastases (P=0.000), number of intracranial metastases < 3 (P=0.003), absence of extracerebral metastases (P=0.000), time of taking medicine ≥ 5 months (P=0.000), and appearance of acneiform rash (P=0.001). On multivariate analysis, time of taking medicine (P=0.000), age (P=0.046), absence of intracranial symptoms (P=0.002) and absence of extracerebral metastases (P=0.000) retained statistical significance. Conclusions: Patients with NSCLC and brain metastasis might benefit from treatment of EGFR-TKI in combination with conventional treatment.

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation.

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases.

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib As 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

Epidermal Growth Factor Receptor (egfr)–tyrosine Kinase Inhibitors (tkis) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

Quick Regression of Brain Metastases from Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Case Report and Literature Review.

Erlotinib for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Hepatic Metastasis is a Poor Predictive Marker for Erlotinib in Lung Adenocarcinoma

Erlotinib As Second-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and Asymptomatic Brain Metastases: A Phase Ii Study (Ctong-0803)

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Risk Factors of Metachronous Brain Metastasis in Patients with EGFR-mutated Advanced Non-Small Cell Lung Cancer

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.

EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Treatment of Brain Metastasis from Non-Small Cell Lung Cancer

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib

Radiotherapy for Asymptomatic Brain Metastasis in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Without Prior Tyrosine Kinase Inhibitors Treatment: a Retrospective Clinical Study

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Phase Ii Study of Whole Brain Radiotherapy with or Without Erlotinib in Patients with Multiple Brain Metastases from Lung Adenocarcinoma

Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases

Combination Therapy of Brain Radiotherapy and EGFR-TKIs is More Effective Than TKIs Alone for EGFR-mutant Lung Adenocarcinoma Patients with Asymptomatic Brain Metastasis

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Conventional Chemotherapy for the Treatment of Non-Small Cell Lung Cancer